With pioneering ADHD data, Alkermes eyes orexin agonist as potential ‘company changer’ 

 ADHD in the News 2026-09-24


Following Takeda’s historic approval of the first orexin agonist with its narcolepsy treatment Orzeyful, Alkermes has followed up with pioneering data that looks to take the hyped drug class out of sleep disorders and into broader patient populations. The neuro specialist today shared that its mimic of the brain protein orexin, which regulates arousal and alertness, alleviated symptoms in a small phase 1b trial of 50 adults with attention deficit hyperactivity disorder (ADHD).

View Article: Fierce Biotech, September 21, 2026




Other Articles in this Edition

Tylenol during pregnancy not linked to autism, ADHD, major review finds 

Padilla, Murphy Introduce Bill to Protect Students from Physical Abuse, End Dangerous Corporal Punishment Practices in Schools

Peer Exchange: Managing Adult ADHD: Addressing Diagnosis, Treatment Selection, and All-Day Symptom Control, EP. 3 & 4 (Opinion)

Adult ADHD: Does Age at Diagnosis Affect Clinical Profile?

Parental Stimulant Medication Added to Parental Behavioral Therapy Led to Better Outcomes for Parent-and-Child Pairs With ADHD 

Navigating roadblocks to autism, ADHD diagnoses for Hispanic families 

Air Force Tech Specialist Faces Potential Discharge Over a Prescribed ADHD Medication 

New Consensus Recommendations for Comprehensive ADHD Monitoring 

Methylphenidate and Lisdexamfetamine Show Comparable Risk for Abuse 

Menstrual Symptoms Linked to Depression, ADHD, and Anxiety in Adolescent Girls 

Meta-analysis Finds Long-term Exercise Associated with Moderate Improvements in Executive Functioning for Children and Adolescents with ADHD 

Children’s pupils may reveal shifting attention in ADHD, especially when off medication

People with similar mental health conditions tend to end up together, raising risk within families 

With pioneering ADHD data, Alkermes eyes orexin agonist as potential ‘company changer’